Clarification Statement

2021-01-31

Sinovac Biotech Ltd. (“Sinovac”) today learned of an English-language statement that was purportedly made in the name of Sinovac. This fraudulent statement (“Fraudulent Statement”) was in no way made or authorized by Sinovac, nor does it reflect the views of Sinovac. The Fraudulent Statement was sent to certain media outlets in Brazil on 30 January 2020, disguised as a valid statement from Sinovac. A number of media have reported about the Fraudulent Statement.

With regard to this, we hereby clarify that:

(i) Abernathy MacGregor is the sole media relation consultant engaged by Sinovac or authorized to communicate or issue statements on its behalf. Sinovac has never authorized or engaged any other company or individual to carry out any public relations activities on behalf of Sinovac.

(ii) Sinovac has never made or issued or engaged any individual or organization to make or issue the Fraudulent Statement.

Sinovac believes that the global fight against the COVID-19 pandemic requires unity and a coordinated response. All of the companies and organizations committed to fighting the pandemic are contributing partners, not competitors.

We oppose any malicious degrading for defamation. Sinovac wishes to condemn the fraudulent behaviors involved with the Fraudulent Statement and the sentiments therein, and reserves all rights to take actions to seek remedies and pursue liabilities against those who have made and published the Fraudulent Statement.

Sinovac Biotech Ltd.

Jan 31, 2021

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.

SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), and the live attenuated varicella vaccine.

SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.

With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.

For more information, please see the Company's website at www.sinovac.com.